• ABL Diagnostics will hold a shareholder meeting in Paris on Sept. 17, 2026.
• Shareholders will vote on a proposal to move the listing from Euronext Paris to Euronext Growth Paris.
• The transfer is planned as a direct admission of existing shares, with no new share issuance.
• The company flagged a €2.41 million free float, or 5.99% of share capital, based on a €2.5 closing price on Aug. 6.
• If approved, the earliest effective transfer date is no earlier than Nov. 17, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ABL Diagnostics SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260807148066) on August 07, 2026, and is solely responsible for the information contained therein.